Related Experiment Video
Updated: Jun 20, 2026

Biofunctionalized Prussian Blue Nanoparticles for Multimodal Molecular Imaging Applications
Published on: April 28, 2015
Blood compatibility of silk nanoparticles: impact of size and dose
Manfred F Maitz1, John D Totten2, Alessia C G Weiss1
1Leibniz-Institut für Polymerforschung Dresden e.V., Division Polymer Biomaterials Science, Hohe Str. 6, 01069 Dresden, Germany.
Abstract:
The increasing application of nanomedicine requires deeper understanding of the interaction of the carrier with the circulatory system, as this system often serves as the gateway for carrier distribution in the body. As foreign materials, nanoparticles can activate blood coagulation and inflammatory systems. However, whether these activation processes respond linearly to the particle count, the interface area with blood, or the total mass remains uncertain. This study incubated 115, 240 or 450 nm diameter silk nanoparticles in vitro in flowing whole human blood at concentrations matching the total mass, total surface area of ideal spherical particles, and particle count and then analyzed the activation of the coagulation cascade, blood platelets, complement cascade and granulocytes. The immunocell association of nanoparticles was highly modulated by plasma proteins, which had a passivating effect. The activation of the humoral cascades mainly depended on the applied mass concentration, whereas granulocyte activation tended to show linear dependence mainly on the particle count, suggesting a direct interaction effect. Additional factors, such as curvature and area restriction for the assembly of enzyme complexes, superposed these effects on basic geometric parameters. Thus, the design of silk nanoparticles for drug delivery has to prioritize either low cell activation or low activation of plasmatic pathways.
Related Concept Videos
Colloids and Suspensions
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are further...
Bioavailability: Influencing Factors
Dose Size and Dosing Frequency: Determination Methods
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

